Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Novartis agreed to a deal worth up to $3.1 billion for Blackstone Life Sciences’ Anthos Therapeutics. Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has ...

Investors with a lot of money to spend have taken a bearish stance on SpringWorks Therapeutics (NASDAQ:SWTX). And retail traders should know. We noticed this today when the trades showed up on ...

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for SpringWorks Therapeutics (NASDAQ:SWTX) revealed 9 unusual trades. Delving into ...

BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor PD-0325901 to be studied in combination Combination approach will target RAS mutations common in many ...

– Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) ...

SpringWorks Therapeutics (SWTX) shares rallied 9% in the last trading session to close at $44.93. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the ...

NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...